Observational studyActas espanolas de psiquiatria2026
Clinical Characteristics and Influencing Factors of Depressive Symptoms in Patients With Vascular Cognitive Impairment.
Observational study in Actas espanolas de psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to characterize depressive symptoms in patients with vascular cognitive impairment (VCI) after ischemic stroke and to identify independent predictors of treatment response to antidepressant therapy, with a focus on lesion-location heterogeneity.
methodsThis retrospective observational cohort study enrolled 224 patients with VCI and concomitant depressive symptoms from June 2022 to June 2024. Depression severity was assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). All patients completed 8 weeks of standardized treatment including antidepressant medication and cognitive rehabilitation. Treatment response was defined as ≥50% reduction in HAMD-17 from baseline to week 8. Lesion locations were categorized into eight mutually exclusive anatomical groups (frontal, temporal, parietal, occipital, basal ganglia/internal capsule, thalamus, pons and cerebellum). Univariate and multivariable logistic regression identified predictors of treatment response, and Receiver Operating Characteristic (ROC) analysis evaluated model performance.
resultsMean baseline HAMD-17 was 27.4 ± 3.1, and 65.2% (146/224) achieved treatment response. Baseline depressive symptom severity differed significantly across lesion locations (one-way analysis of variance (ANOVA): F (7,216) = 3.48, p = 0.001), whereas baseline anxiety severity did not (F (7,216) = 0.72, p = 0.652). In multivariable analysis, lower baseline Hamilton Anxiety Rating Scale (HAMA) score (odds ratio (OR) = 0.93, 95% confidence interval (CI): 0.88-0.98, p = 0.006), shorter time since stroke (OR = 0.86 per month, 95% CI: 0.75 to 0.99, p = 0.034), and higher education-adjusted Montreal Cognitive Assessment (MoCA) score (OR = 1.12 per point, 95% CI: 1.01-1.24, p = 0.031) were independently associated with treatment response. The prediction model demonstrated moderate discriminative ability (area under the curve (AUC) = 0.795, 95% CI: 0.738-0.851), with sensitivity of 0.890 and specificity of 0.608 at the optimal cutoff.
conclusionsDepressive symptom burden in poststroke VCI exhibits significant anatomical heterogeneity across lesion locations. Baseline anxiety severity, disease duration, and baseline cognitive performance moderately predict treatment response, supporting early risk stratification and individualized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.